We are live on ! Find out more
SL

Siren LLC Portfolio holdings

AUM $3.61B
1-Year Est. Return 203.3%
This Fund
S&P 500
This Quarter Est. Return
+18.65%
1 Year Est. Return
+203.3%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.93B
AUM Growth
+$160M
Cap. Flow
+$578K
Cap. Flow %
0.03%
Top 10 Hldgs %
48.49%
Holding
131
New
15
Increased
21
Reduced
19
Closed
21

Top Buys

Rank Stock Value
1
DYN icon
Dyne Therapeutics
DYN
+$23.3M
2
BCAX
Bicara Therapeutics
BCAX
+$23.2M
3
EWTX icon
Edgewise Therapeutics
EWTX
+$21.1M
4
MLTX icon
MoonLake Immunotherapeutics
MLTX
+$20.7M
5
AVBP icon
ArriVent BioPharma
AVBP
+$14.5M

Top Sells

Rank Stock Value
1
BPMC
Blueprint Medicines
BPMC
+$64.3M
2
SLNO
Soleno Therapeutics
SLNO
+$19.5M
3
PRTA icon
Prothena Corp
PRTA
+$15.9M
4
SMMT icon
Summit Therapeutics
SMMT
+$13.4M
5
NAMS icon
NewAmsterdam Pharma
NAMS
+$13.1M

Sector Composition

Rank Sector Weight
1 Healthcare 90.42%
2 Technology 4.93%
3 Communication Services 2.51%
4 Consumer Discretionary 1.07%
5 Real Estate 0.77%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MLTX icon
26
MoonLake Immunotherapeutics
MLTX
$1.55B
$24M 1.24%
+508,267
New +$20.7M
SEPN
27
Septerna Inc
SEPN
$1.75B
$23.3M 1.2%
2,202,514
– –
NAMS icon
28
NewAmsterdam Pharma
NAMS
$3.34B
$21.6M 1.12%
1,194,240
-717,790
-38% -$13.1M
TRVI icon
29
Trevi Therapeutics
TRVI
$2.63B
$21.5M 1.11%
3,938,793
+1,075,000
+38% +$6.69M
TNGX icon
30
Tango Therapeutics
TNGX
$4.41B
$17.2M 0.89%
3,364,814
+799,472
+31% +$1.98M
AKRO
31
DELISTED
Akero Therapeutics
AKRO
$17M 0.88%
+318,647
New +$14.5M
SLN
32
Silence Therapeutics
SLN
$564M
$16.9M 0.87%
2,911,438
+121,605
+4% +$521K
AVBP icon
33
ArriVent BioPharma
AVBP
$1.44B
$15.2M 0.79%
+700,000
New +$14.5M
BCYC
34
Bicycle Therapeutics
BCYC
$292M
$14M 0.72%
2,012,752
+200,000
+11% +$1.59M
RCUS icon
35
Arcus Biosciences
RCUS
$3.64B
$13.1M 0.68%
1,612,077
– –
IHS icon
36
IHS Holding
IHS
$2.81B
$13.1M 0.68%
2,357,520
– –
AMZN icon
37
Amazon
AMZN
$2.96T
$12.4M 0.64%
56,500
– –
DNLI icon
38
Denali Therapeutics
DNLI
$3.94B
$11.5M 0.59%
821,513
– –
ERAS icon
39
Erasca
ERAS
$6.39B
$11.1M 0.58%
8,757,249
– –
ORIC icon
40
Oric Pharmaceuticals
ORIC
$1.4B
$10.2M 0.53%
1,007,575
– –
RELY icon
41
Remitly
RELY
$5.14B
$9.67M 0.5%
515,449
+25,000
+5% +$520K
PCVX icon
42
Vaxcyte
PCVX
$8.64B
$9.61M 0.5%
295,543
– –
CRWD icon
43
CrowdStrike
CRWD
$218B
$9.42M 0.49%
74,000
-26,000
-26% -$2.82M
CGEM icon
44
Cullinan Oncology
CGEM
$1.14B
$8.99M 0.47%
1,193,410
– –
GOOGL icon
45
Alphabet (Google) Class A
GOOGL
$4.33T
$8.93M 0.46%
50,703
– –
UPB
46
Upstream Bio Inc
UPB
$395M
$8.66M 0.45%
788,450
– –
SEER icon
47
Seer Inc
SEER
$120M
$8.56M 0.44%
4,000,000
– –
MSFT icon
48
Microsoft
MSFT
$3.71T
$8.03M 0.42%
16,150
-12,350
-43% -$5.36M
NVDA icon
49
NVIDIA
NVDA
$5.42T
$7.9M 0.41%
49,985
+5,553
+12% +$699K
IONQ icon
50
IonQ
IONQ
$16.6B
$7.3M 0.38%
170,000
– –
1
2
3 4 5

Similar funds

SCM
Saba Capital Management New York $3.62B AUM 12.96% 1-Year Est. Return
ACM
Advent Capital Management New York $3.63B AUM 0.29% 1-Year Est. Return
GCM
Ghisallo Capital Management Boston, Massachusetts $3.63B AUM 30.51% 1-Year Est. Return
VI
Vestcor Inc Fredericton, New Brunswick, Canada $3.63B AUM 21.49% 1-Year Est. Return
BPS
BNDES Participacoes SA Rio De Janeiro, Brazil $3.58B AUM
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
WWA
WCG Wealth Advisors Las Vegas, Nevada $3.57B AUM 18.63% 1-Year Est. Return
OCM
One Capital Management Westlake Village, California $3.65B AUM 15.32% 1-Year Est. Return

Siren LLC's Q2 2025 Portfolio in Review

As of Q2 2025, Siren LLC held 131 positions worth $1.93B, up 9% from $1.77B the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Siren LLC's Q2 2025 filing shows 15 new, 21 increased, 19 reduced and 21 closed positions. Its largest new stake was MoonLake Immunotherapeutics: 508,267 shares worth $24M. The largest sale was Blueprint Medicines, an estimated $64.3M.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, up from 90% a quarter earlier, followed by Technology and Communication Services.

  • Siren LLC's largest Q2 2025 buy was MoonLake Immunotherapeutics: 508,267 shares worth $24M.
  • Siren LLC added most to Dyne Therapeutics in Q2 2025, an estimated $23.3M increase.
  • Siren LLC's biggest Q2 2025 reduction was Soleno Therapeutics, cutting an estimated $19.5M.
  • Siren LLC fully exited Blueprint Medicines in Q2 2025, selling an estimated $64.3M.
  • Siren LLC's ten largest holdings make up 48% of its $1.93B portfolio in Q2 2025.
  • Siren LLC opened 15 new positions and closed 21 in Q2 2025.
  • Siren LLC's portfolio value rose 9% quarter-over-quarter to $1.93B.

Based on Siren LLC's 13F filing for Q2 2025, filed 13 Aug 2025.